U.S., Sept. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07811999) titled 'Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC Injections' on Sept. 04.
Brief Summary: The primary objective of this trial is to evaluate the relative bioavailability of romosozumab administered as a single 2.34 mL subcutaneous (SC) injection from a prefilled syringe (PFS) or 2 x 1.17 mL SC injections from PFS in healthy participants.
Study Start Date: Sept. 22
Study Type: INTERVENTIONAL
Condition:
Healthy Participants
Intervention:
DRUG: Romosozumab
Romosozumab will be administered via SC injection using a PFS.
Recruitment Status: NOT_...